MELBOURNE, May 16, 2026, 03:08 AEST
CSL Limited finished Friday barely above its 52-week low, with the Australian biotech facing renewed scrutiny. A recent profit warning and plans for write-downs have rattled confidence in a stock once seen as an ASX standout.
Shares finished at A$97.96, gaining 0.72% for the session. Over the last week, though, the stock has slumped 19.7%, Intelligent Investor data show. It touched a 52-week low of A$97.26 on Thursday.
This shift lands at a critical moment for CSL, which now faces more than just a growth pause—its credibility is on the line. The company’s 90-day review, out Monday, lowered its projected fiscal 2026 revenue to around $15.2 billion. NPATA—net profit after tax before amortisation of acquired IP and major one-offs—is now expected to reach about $3.1 billion, both numbers presented at constant currency to adjust for exchange rate fluctuations.
The update also pointed to roughly $5 billion more in non-cash, pre-tax impairments spread over fiscal 2026 and 2027. This type of impairment—essentially an accounting write-down—hits the value of assets on the books, without triggering an instant cash payment. Still, it can indicate those earlier investments aren’t holding their expected value.
Interim Chief Executive Gordon Naylor didn’t mince words. “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated,” he said in the company’s ASX filing. The review points to an estimated $300 million revenue shortfall tied to U.S. immunoglobulin—antibody-based plasma therapies. Another $200 million comes from softer albumin pricing in China. Around $150 million is linked to a mix of issues: Middle East disruptions, HEMGENIX’s slower growth, and iron market competition.
CSL shares plunged as much as 22% on Monday, Bloomberg said, erasing roughly A$10 billion from the company’s market cap after it slashed its full-year guidance and signaled the turnaround won’t be quick. The sell-off was stark.
CSL isn’t facing a problem with just a single product. The headache stems from a mix of factors: excess U.S. immunoglobulin inventory in distribution, softer albumin pricing across China, plus some lagging assets linked to Vifor—the Swiss iron and kidney treatment group CSL acquired back in 2022.
Naylor reassured investors Monday there’s “no fundamental shift in business strategy,” framing the challenge as “primarily about excellence in execution,” according to Fierce Pharma. Jefferies analysts, also quoted by the publication, noted the downgrade wasn’t a shock given persistent issues in U.S. immunoglobulin and China albumin. Those segments, they said, still have room to grow over the medium term. Fierce Pharma
Competition is definitely in the mix. Takeda, Grifols, and CSL Behring stand out in market reports as the big names in immunoglobulin, while CSL’s filing also highlighted mounting iron competition as a factor dragging its revised guidance.
Vaccines offered a rare bright spot, but it didn’t do much to sway sentiment. In a JAMA Network Open study covering 429,595 adults 65 and older, CSL Seqirus’ adjuvanted flu shot — which contains an extra component to enhance immunity — performed on par with high-dose flu vaccines for stopping lab-confirmed influenza in the 2023-24 season.
Gregg Sylvester, chief medical officer and head of research and development at CSL Seqirus, called the results “important new evidence,” noting in the company’s release that this ranks among the largest real-world, cluster-randomized influenza vaccine studies. Global Newsroom | CSL
CSL Seqirus has inked a multi-year pact with the Pan American Health Organization’s Regional Revolving Fund, securing millions of pandemic influenza vaccine doses for Latin American and Caribbean nations. “When the next influenza pandemic strikes,” said Gonzalo Pereira, CSL Seqirus’ Latin America general manager, the agreement will mean the region has manufacturing capacity on the ground and better access to vaccines. Global Newsroom | CSL
The fix leaves almost no margin for missteps. More stress in China albumin, a drag from sluggish U.S. inventory cleanup, underperforming Vifor products, or new audit revisions could all drag out the reset process. CSL flagged that impairments still hinge on additional scrutiny, business shifts, the external audit, and board sign-off.
Investors are circling Aug. 18 on their calendars—that’s when CSL hands down its full-year financials and operational update. Until that release, the company faces scrutiny not for its general commentary, but for proof that plasma, vaccines, and Vifor aren’t tugging the business in separate directions.
